Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis

IF 14 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Clinical and Molecular Hepatology Pub Date : 2025-02-05 DOI:10.3350/cmh.2024.0609
Haiyu Wang, Weihao Liang, Ling Zhou, Jiankang Song, Biao Wen, Qiaoping Wu, Yuanjian Zhang, Xiaofeng Zhang, Haoran Ke, Yujun Tang, Fuyuan Zhou, Youfu Zhu, Weiqun Wen, Zhihua Liu, Yali Ji, Qintao Lai, Qinjun He, Wenfan Luo, Tingting Qi, Miaoxia Liu, Xiaoqin Lan, Yongpeng Chen, Ranran Xi, Junting Wan, Lin Dai, Yuan Li, Jinjun Chen
{"title":"Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis","authors":"Haiyu Wang, Weihao Liang, Ling Zhou, Jiankang Song, Biao Wen, Qiaoping Wu, Yuanjian Zhang, Xiaofeng Zhang, Haoran Ke, Yujun Tang, Fuyuan Zhou, Youfu Zhu, Weiqun Wen, Zhihua Liu, Yali Ji, Qintao Lai, Qinjun He, Wenfan Luo, Tingting Qi, Miaoxia Liu, Xiaoqin Lan, Yongpeng Chen, Ranran Xi, Junting Wan, Lin Dai, Yuan Li, Jinjun Chen","doi":"10.3350/cmh.2024.0609","DOIUrl":null,"url":null,"abstract":"<p><strong>Background & aims: </strong>Cirrhotic patients with liver stiffness measurement (LSM) <20kPa and platelet count ≥150/ul (Baveno VI criteria), otherwise spleen stiffness measurement (SSM) ≤ 40kPa (Baveno VI-SSM criteria) can avoid endoscopy screening, however, no prospective data for their hepatic outcomes.</p><p><strong>Methods: </strong>Compensated cirrhosis with chronic hepatitis B were prospectively enrolled from April 2019 to April 2022 and followed until July 2023. All patients underwent LSM, SSM and esophagogastroduodenoscopy (EGD) assessment.</p><p><strong>Results: </strong>Among 1224 patients enrolled with median follow-up of 30 months (IQR 21-42), the incidence of decompensation was greater in 560 patients with unfavored Baveno-VI criteria (0.5 vs. 20.4 per 1,000 person-years, p=0.0004) than that in 664 patients with favored Baveno-VI-SSM criteria. The Baveno VI-SSM model identified more patients (54.2%) into low-risk for decompensation than Baveno VII-SSM model (single cutoff) (48.4%, p=0.004) and than Baveno VI criteria (34.6%, p<0.0001) did. Patients with high-risk varices diagnosed via endoscopy following Baveno VI-SSM model assessment had greater probability of decompensation compared to those identified by the Baveno VII-SSM model (single cutoff) (42.8 vs. 21.1 per 1,000 person-years, p=0.0088). Additionally, among the 493 patients who underwent endoscopic re-assessment, 242 patients with favored Baveno VI-SSM criteria had much lower incidence of EV progression (2.6 vs. 99.5 per 1,000 person-years, p=0.0004) and lower risk of decompensation compared to 140 patients with unfavored Baveno VI-SSM model (0 vs. 34.2 per 1,000 person-years, p=0.0256).</p><p><strong>Conclusions: </strong>Baveno VI-SSM model could identify chronic hepatitis B-related cirrhosis patients at low risk of decompensation, which was greatly improved upon Baveno VI-SSM reassessment.</p>","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":14.0000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Molecular Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3350/cmh.2024.0609","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background & aims: Cirrhotic patients with liver stiffness measurement (LSM) <20kPa and platelet count ≥150/ul (Baveno VI criteria), otherwise spleen stiffness measurement (SSM) ≤ 40kPa (Baveno VI-SSM criteria) can avoid endoscopy screening, however, no prospective data for their hepatic outcomes.

Methods: Compensated cirrhosis with chronic hepatitis B were prospectively enrolled from April 2019 to April 2022 and followed until July 2023. All patients underwent LSM, SSM and esophagogastroduodenoscopy (EGD) assessment.

Results: Among 1224 patients enrolled with median follow-up of 30 months (IQR 21-42), the incidence of decompensation was greater in 560 patients with unfavored Baveno-VI criteria (0.5 vs. 20.4 per 1,000 person-years, p=0.0004) than that in 664 patients with favored Baveno-VI-SSM criteria. The Baveno VI-SSM model identified more patients (54.2%) into low-risk for decompensation than Baveno VII-SSM model (single cutoff) (48.4%, p=0.004) and than Baveno VI criteria (34.6%, p<0.0001) did. Patients with high-risk varices diagnosed via endoscopy following Baveno VI-SSM model assessment had greater probability of decompensation compared to those identified by the Baveno VII-SSM model (single cutoff) (42.8 vs. 21.1 per 1,000 person-years, p=0.0088). Additionally, among the 493 patients who underwent endoscopic re-assessment, 242 patients with favored Baveno VI-SSM criteria had much lower incidence of EV progression (2.6 vs. 99.5 per 1,000 person-years, p=0.0004) and lower risk of decompensation compared to 140 patients with unfavored Baveno VI-SSM model (0 vs. 34.2 per 1,000 person-years, p=0.0256).

Conclusions: Baveno VI-SSM model could identify chronic hepatitis B-related cirrhosis patients at low risk of decompensation, which was greatly improved upon Baveno VI-SSM reassessment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical and Molecular Hepatology
Clinical and Molecular Hepatology Medicine-Hepatology
CiteScore
15.60
自引率
9.00%
发文量
89
审稿时长
10 weeks
期刊介绍: Clinical and Molecular Hepatology is an internationally recognized, peer-reviewed, open-access journal published quarterly in English. Its mission is to disseminate cutting-edge knowledge, trends, and insights into hepatobiliary diseases, fostering an inclusive academic platform for robust debate and discussion among clinical practitioners, translational researchers, and basic scientists. With a multidisciplinary approach, the journal strives to enhance public health, particularly in the resource-limited Asia-Pacific region, which faces significant challenges such as high prevalence of B viral infection and hepatocellular carcinoma. Furthermore, Clinical and Molecular Hepatology prioritizes epidemiological studies of hepatobiliary diseases across diverse regions including East Asia, North Asia, Southeast Asia, Central Asia, South Asia, Southwest Asia, Pacific, Africa, Central Europe, Eastern Europe, Central America, and South America. The journal publishes a wide range of content, including original research papers, meta-analyses, letters to the editor, case reports, reviews, guidelines, editorials, and liver images and pathology, encompassing all facets of hepatology.
期刊最新文献
GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma. Interventions Targeting the Gut-Liver Axis: A Potential Treatment Strategy for MASLD. Letter to the editor on "Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis". Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis Correspondence to Editorial on "Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma".
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1